Sandra Sobel
Internal Medicine · Pittsburgh, PANPI 1851550891
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $134,966 of the $175,927 with a category attached, or 76.7%. Novo Nordisk accounts for 62.1% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $86,998, more than ten times the $247 reported in 2019. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 176 payments — averaging $999.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$109K
- Lilly USA, LLC$55K
- Sanofi-aventis U.S. LLC$8K
- Bayer$2K
- Cequr Corporation$413
- Dexcom, Inc.$135
- plus $356 from 6 others
Across 1 payment — averaging $2291.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$2K
What the payments were for
- Consulting fees$18,75011%
- Speaking & faculty fees$134,96677%
- Travel & lodging$18,07610%
- Food & beverage$4,0762%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 91 | $109,304 |
| Lilly USA, LLC | 60 | $55,317 |
| Sanofi-aventis U.S. LLC | 11 | $8,249 |
| Bayer | 1 | $2,153 |
| Cequr Corporation | 1 | $413 |
| Dexcom, Inc. | 2 | $135 |
| Insulet Corporation | 1 | $86 |
| Tandem Diabetes Care, Inc. | 3 | $73 |
| BD | 1 | $71 |
| Mannkind Corporation | 1 | $59 |
| AbbVie | 2 | $42 |
| Abbott | 2 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$78,185
- ZEPBOUND$50,728
- Saxenda$7,149
- Lynkuet$2,153
- CeQur Simplicity$413
- Ozempic$122
- DEXCOM G6 TRANSMITTER$117
- TZIELD$114
How this compares
$175,927 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 27 | $51,956 |
| OzempicSemaglutide | 31 | $36,621 |
| JardianceEmpagliflozin | 18 | $17,164 |
| RybelsusSemaglutide | 14 | $12,833 |
| SynthroidLevothyroxine Sodium | 23 | $1,064 |
| Levothyroxine Sodium | 12 | $21 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $55,317 | $51,95627 claims |
| Novo NordiskOzempic, Rybelsus | $109,304 | $49,45445 claims |
| AbbVieSynthroid | $42 | $1,06423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Pittsburgh
- Donald MiddletonPittsburgh$258K
- Enrico NovelliPittsburgh$176K
- Abdullah AzharPittsburgh$120K
- Bassel SayeghPittsburgh$77K
- Liza VillaruzPittsburgh$53K
- David MillerPittsburgh$50K
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.